Leads Biolabs Gains HKEX Approval for Full H-Share Circulation, Converting 44.39 Million Unlisted Shares

Bulletin Express05-14

Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) announced that The Stock Exchange of Hong Kong Limited approved on 14 May 2026 the listing of 44.39 million newly-converted H shares, marking the formal launch of the company’s H-share full-circulation programme.

Upon completion of the conversion and listing:

• Total H shares will rise from 153.28 million to 197.67 million, lifting the proportion of H shares in issue from 77.07% to 99.39% of the company’s 198.89 million total shares. • Unlisted domestic shares will fall from 45.61 million to 1.22 million, reducing their stake from 22.93% to 0.61%.

Participation details

• 23 shareholders are converting a combined 44.39 million unlisted shares, equal to 22.32% of the company’s enlarged H-share capital. • The three largest converting holders are: – Loyal Valley Capital Advantage Fund III LP: 9.99 million shares (5.02% of total equity). – Nanjing Lizhi Management & Consulting Center (L.P.): 6.42 million shares (3.23%). – Dr. Kang Xiaoqiang, Chairman and CEO: 3.94 million shares (1.98%).

Next steps

Leads Biolabs will complete the requisite conversion and trading procedures and will issue further announcements in line with Hong Kong’s Listing Rules and Inside Information provisions. Shareholders and potential investors are urged to exercise caution when dealing in the company’s securities.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1178818679?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-14 21:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1178818679","market":"hk","top_or_hot":-1,"title":"Leads Biolabs Gains HKEX Approval for Full H-Share Circulation, Converting 44.39 Million Unlisted Shares","media":"Bulletin Express","content":"<p>Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) announced that The Stock Exchange of Hong Kong Limited approved on 14 May 2026 the listing of 44.39 million newly-converted H shares, marking the formal launch of the company’s H-share full-circulation programme.</p>\n<p>Upon completion of the conversion and listing:</p>\n<p>• Total H shares will rise from 153.28 million to 197.67 million, lifting the proportion of H shares in issue from 77.07% to 99.39% of the company’s 198.89 million total shares.  \n• Unlisted domestic shares will fall from 45.61 million to 1.22 million, reducing their stake from 22.93% to 0.61%.</p>\n<p>Participation details</p>\n<p>• 23 shareholders are converting a combined 44.39 million unlisted shares, equal to 22.32% of the company’s enlarged H-share capital.  \n• The three largest converting holders are:  \n  – Loyal Valley Capital Advantage Fund III LP: 9.99 million shares (5.02% of total equity).  \n  – Nanjing Lizhi Management & Consulting Center (L.P.): 6.42 million shares (3.23%).  \n  – Dr. Kang Xiaoqiang, Chairman and CEO: 3.94 million shares (1.98%).</p>\n<p>Next steps</p>\n<p>Leads Biolabs will complete the requisite conversion and trading procedures and will issue further announcements in line with Hong Kong’s Listing Rules and Inside Information provisions. Shareholders and potential investors are urged to exercise caution when dealing in the company’s securities.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Leads Biolabs Gains HKEX Approval for Full H-Share Circulation, Converting 44.39 Million Unlisted Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLeads Biolabs Gains HKEX Approval for Full H-Share Circulation, Converting 44.39 Million Unlisted Shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-14 21:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) announced that The Stock Exchange of Hong Kong Limited approved on 14 May 2026 the listing of 44.39 million newly-converted H shares, marking the formal launch of the company’s H-share full-circulation programme.</p>\n<p>Upon completion of the conversion and listing:</p>\n<p>• Total H shares will rise from 153.28 million to 197.67 million, lifting the proportion of H shares in issue from 77.07% to 99.39% of the company’s 198.89 million total shares.  \n• Unlisted domestic shares will fall from 45.61 million to 1.22 million, reducing their stake from 22.93% to 0.61%.</p>\n<p>Participation details</p>\n<p>• 23 shareholders are converting a combined 44.39 million unlisted shares, equal to 22.32% of the company’s enlarged H-share capital.  \n• The three largest converting holders are:  \n  – Loyal Valley Capital Advantage Fund III LP: 9.99 million shares (5.02% of total equity).  \n  – Nanjing Lizhi Management & Consulting Center (L.P.): 6.42 million shares (3.23%).  \n  – Dr. Kang Xiaoqiang, Chairman and CEO: 3.94 million shares (1.98%).</p>\n<p>Next steps</p>\n<p>Leads Biolabs will complete the requisite conversion and trading procedures and will issue further announcements in line with Hong Kong’s Listing Rules and Inside Information provisions. Shareholders and potential investors are urged to exercise caution when dealing in the company’s securities.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09887","symbol_name":"维立志博-B","start_time":0,"source_url":"","article_id":"1178818679","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1178818679","pubTimestamp":1778764971,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) announced that The Stock Exchange of Hong Kong Limited approved on 14 May 2026 the listing of 44.39 million newly-converted H shares, marking the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09887":"维立志博-B"},"translate_title":"Leads Biolabs获港交所批准H股全流通转换4439万股非上市股份","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09887":1},"content_text":"Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) announced that The Stock Exchange of Hong Kong Limited approved on 14 May 2026 the listing of 44.39 million newly-converted H shares, marking the formal launch of the company’s H-share full-circulation programme.\nUpon completion of the conversion and listing:\n• Total H shares will rise from 153.28 million to 197.67 million, lifting the proportion of H shares in issue from 77.07% to 99.39% of the company’s 198.89 million total shares.  \n• Unlisted domestic shares will fall from 45.61 million to 1.22 million, reducing their stake from 22.93% to 0.61%.\nParticipation details\n• 23 shareholders are converting a combined 44.39 million unlisted shares, equal to 22.32% of the company’s enlarged H-share capital.  \n• The three largest converting holders are:  \n  – Loyal Valley Capital Advantage Fund III LP: 9.99 million shares (5.02% of total equity).  \n  – Nanjing Lizhi Management & Consulting Center (L.P.): 6.42 million shares (3.23%).  \n  – Dr. Kang Xiaoqiang, Chairman and CEO: 3.94 million shares (1.98%).\nNext steps\nLeads Biolabs will complete the requisite conversion and trading procedures and will issue further announcements in line with Hong Kong’s Listing Rules and Inside Information provisions. Shareholders and potential investors are urged to exercise caution when dealing in the company’s securities.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1178818679","isCrawlerRequest":true}